Breye Therapeutics
Clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases.
Breye Therapeutics is a biotech & life sciences company based in DK, founded in 2019. It has raised $75.77 million in disclosed funding. Its latest round was a Series A of €67.5 million in October 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $75.8M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| €67.5M | Series A | Mission BioCapital, Novo Holdings | Sound Bioventures +6 | Biotech & Life Sciences | 1 |
- Breye Therapeutics€67.5M
Led by Mission BioCapital, Novo Holdings · with Sound Bioventures, +6
Investors
Questions and answers
What does Breye Therapeutics do?
Clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases.
How much has Breye Therapeutics raised?
Breye Therapeutics has raised $75.77 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Breye Therapeutics?
Investors in Breye Therapeutics include Mission BioCapital, Novo Holdings, Sound Bioventures, Ljungström family office, Innovestor Life Science and 4 more.
When and where was Breye Therapeutics founded?
Breye Therapeutics was founded in 2019 and is based in DK.
Timeline
Founded
Sources
- 1.Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases — EU-Startups, Oct 2, 2026